| Date | Title | | | | 06/13/13 | Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program| -- Enrollment Expected to Begin Next Month --
SEATTLE, June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safet... |
| |  | | 05/31/13 | Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial| -- OMS824 Achieves High Target Occupancy without Causing Movement Disorders Seen with Other PDE10 Inhibitors --
SEATTLE, May 31, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. This study measured the extent to which OMS824 binds to PDE10 in the basal ganglia, a region of the brain that has been linked to a wide range of diseases that af... |
| | | | 05/28/13 | Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program| -- Phase 1 Clinical Trial Expected to Begin Early Next Quarter --
SEATTLE, Wash., May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The lead indication for OMS721 will be atypical hemolytic uremic syndrome (aHUS), a rare... |
| | | | 05/23/13 | Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease| -- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter --
SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect ... |
| | | | 05/22/13 | Omeros to Present at Two Upcoming Conferences| SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences:
38th Annual Deutsche Bank dbAccess Health Care Conference
May 29, 2013
2:10 p.m. EDT
Boston, MA
Jeff... |
| | | | 05/14/13 | Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock| SEATTLE, May 14, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013. The shares were sold at a price of $4.14 per share, which represented a two percent premium over the closing price on May 8, 2013. The shares were sold directly to affiliates of RA Capital Management and other investors without an underwriter or placement agent. Omeros received net proceed... |
| | | | 05/10/13 | Omeros Corporation Reports First Quarter 2013 Financial Results| SEATTLE, May 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013.
Financial Results
Total operating expenses for the quarter ended March 31, 2013 were $11.1 million compared to $9.6 million for the same period in 2012. The ... |
| | | | 05/09/13 | Omeros Announces $16.2 Million Registered Direct Offering of Common Stock| SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, af... |
| | | | 05/01/13 | Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease| -- Phase 2 Clinical Trial Slated to Begin This Year --
SEATTLE, May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of OMS824 for the treatment of Huntington's disease. OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease... |
| | | | 04/30/13 | Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review| -- Centralized Procedure Used for Products that Represent Therapeutic Innovation --
SEATTLE, April 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application (MAA) for its ophthalmology product OMS302 can be submitted and reviewed under the EMA's centralized procedure. OMS302, which contains mydriatic (pupil-dilating) and anti-inflammatory agents, is the Compan... |
| | | | 04/25/13 | Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress| -- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis --
SEATTLE, April 25, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302, which contains a mydriatic (pupil-dilating) agent and an anti-inflammato... |
| | | | 04/24/13 | Omeros to Present at the 12th Annual Needham Healthcare Conference| SEATTLE, April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12th Annual Needham Healthcare Conference next week. Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 8:40 a.m. Eastern Time on Wednesday, May 1, 2013.
The pres... |
| | | | 04/19/13 | Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress| SEATTLE, April 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress taking place in San Francisco April 19-23. The podium presentation, "Effect of an Anti-inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis Du... |
| | | | 04/17/13 | Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721| -- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review --
SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP‑2) program, for use in the treatment of atypical hemolytic uremic syndrome (aHUS). As Om... |
| | | | 04/10/13 | Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis| - Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients -
SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPC... |
| | | | 04/02/13 | Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy| -- Support Advancing Initial Clinical Indication of Atypical Hemolytic Uremic Syndrome --
SEATTLE, April 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of thrombotic microangiopathy (TMA), a disorder that occurs in the microcirculation (e.g., venules and capillaries) of the body's organs, mo... |
| | | | 03/29/13 | Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference| SEATTLE, March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference. Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time on Friday, April 5, 2... |
| | | | 03/28/13 | Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials| -- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 --
SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology (still o... |
| | | | 03/26/13 | Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial| -- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors --
SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this clinical t... |
| | | | 03/19/13 | Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction| -- Clinical Entry Planned for Second Half of 2013 --
SEATTLE, March 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has elucidated the mechanism of action of its phosphodiesterase 7 (PDE7) inhibitors in the neural network shown to be responsible for addiction in humans. Omeros believes that it is the first to discover the link between PDE7 and any addiction or compulsive disorder, and the Company is establishing a broad intellectual property position around ... |
| | | | 03/18/13 | Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results| SEATTLE, March 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012.
Financial Results
Total operating expenses for the three months ended December 31, 2012 were $9.1 million, compared to $11.0 million ... |
| | | | 03/01/13 | Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference|
SEATTLE, March 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference next week. The presentation is scheduled for 11:20 a.m. Eastern Time... |
| | | | 02/07/13 | Omeros Announces Toxicology Study Data from MASP-2 Inhibitor| -- IND/CTA Submission Expected in the Second Quarter of 2013 --
SEATTLE, Feb. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin associated serine protease-2 (MASP-2) program. Based on the data from these nonhuman primate studies, OMS721 is expected to be delivered subcutaneously to patients at a convenient dosing schedule of weekly, bi-monthly or even les... |
| | | | 01/22/13 | Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial| -- Market Launch Expected First Half of 2014 --
SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product desi... |
| | | | 01/16/13 | Omeros Identifies Small Molecules for Class B GPCR| - Expands "Unlocking" Capability Beyond Class A Orphan GPCRs -
SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G Protein-Coupled Receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad r... |
| | |
|
Receive E-mail Alerts | 
RSS Feeds
